{"entity":{"id":"epitope-spreading","kind":"term","name":"Epitope spreading","aka":[],"tldr":"An immune response can broaden to recognize additional epitopes over time. Showing that broadening requires measurements of the added specificities.","summary":"A follow-up study of a small melanoma neoantigen-vaccine cohort found persistent immune responses, evolving receptor clonotypes and evidence of responses beyond the original vaccine targets. The report provides clinical immune-monitoring evidence of spreading in that cohort. The response measurements are distinct from a randomized estimate of treatment benefit. Spreading should not be inferred solely from an increased total lymphocyte count or expansion of an unidentified receptor sequence.","asOf":"2026-11-09","links":[{"label":"Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma.","url":"https://doi.org/10.1038/s41591-020-01206-4"},{"label":"Hu et al., Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma (Nat Med 2021)","url":"https://pubmed.ncbi.nlm.nih.gov/33479501/"},{"label":"Ott et al., An immunogenic personal neoantigen vaccine for patients with melanoma (Nature 2017)","url":"https://pubmed.ncbi.nlm.nih.gov/28678778/"}],"tags":[],"related":["immunogenicity-versus-efficacy","tcr-repertoire-sequencing","immunodominance"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Epitope spreading is additional detected recognition beyond the initially targeted epitope set, potentially within one source protein or across proteins. More response to the same target is expansion. Responses to both directly encoded A and B do not themselves demonstrate spreading. Newly detected is not newly created: baseline sensitivity can miss pre-existing responsive cells.","Tumour injury can release additional antigen for uptake and presentation, but one follow-up response does not establish that entire causal chain. Define peptide-HLA targets and compare matched baseline and follow-up assays with background, presentation and cross-reactivity controls; assess intervening treatment. Vaccine recruitment or expansion does not normally rewrite mature TCRs. An immune response, including one to healthy self, does not establish recurrence prevention, safety or clinical benefit.","In a fictional A/B vaccine experiment, baseline C is undetectable and matched follow-up detects unencoded C, consistent with an additional detected specificity. The A-cell icons are qualitative, not counts. Ten additional receptor sequences without target testing demonstrate repertoire change, not recognition of C; causation and patient benefit remain separate questions."],"category":"Immunology"},"route":"/terms/epitope-spreading/","neighbours":{"term":[{"id":"immune-product-evidence","kind":"term","name":"Immune measurements and product evidence","route":"/terms/immune-product-evidence/"},{"id":"immunodominance","kind":"term","name":"Immunodominance","route":"/terms/immunodominance/"},{"id":"immunogenicity-versus-efficacy","kind":"term","name":"Immunogenicity and clinical efficacy","route":"/terms/immunogenicity-versus-efficacy/"},{"id":"tcr-repertoire-sequencing","kind":"term","name":"T-cell receptor repertoire sequencing","route":"/terms/tcr-repertoire-sequencing/"}]}}